Business
Final Results
Final Results.
About this update from Shield Therapeutics Plc
[{"type":"text","content":"\n \nRNS Number : 9068U Shield Therapeutics PLC 03 April 2019 \n\n \nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\n \nPreliminary Results for the Year Ended 31 December 2018\n \nLondon, UK, 3 April 2019. Shield Therapeutics plc (LSE:STX), a commercial stage, pharmaceutical company with an initial focus on addressing iron deficiency, announces its preliminary Group results for the year ended 31 December 2018.\n \nOperational Highlights\n· Positive results for pivotal Phase III AEGIS-CKD study of Feraccru® vs. placebo\n· Approved label significantly broadened in Europe to all adults with Iron Deficiency with or without anaemia - a market of 40 million patients\n· Exclusive licence agreement with Norgine B.V. to commercialise Feraccru® in Europe, Australia and New Zealand\n- £11 million upfront payment\n- up to €54.5 million milestone payments\n- up to 40% sales royalties\n· Recruitment completed for AEGIS-H2H Phase IIIb study of oral Feraccru® vs. intravenous iron therapy\n· US New Drug Application accepted for review by FDA; 27 July 2019 target (\"PDUFA\") date for review completion\n \nFinancial Highlights\n· Revenues of £11.9 million (2017: £0.6 million)\n· Loss for the year of £1.8 million (2017: £19.6...